Bifogade filer
Neola Medical’s CEO shares spring milestones and strengthened shareholder base in 2025 investor letter
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
As 2025 unfolds, Neola Medical highlights key progress in clinical development and financing. The company has received approval from Swedish authorities to initiate its first clinical study on preterm born babies in Sweden and has completed a successful directed share issue of approximately SEK 20 million, strengthening its shareholder base with the addition of new institutional investors alongside existing shareholders.
“We have received approval from Swedish authorities to initiate our first clinical pilot study in Sweden, marking a major milestone as Neola® will be used for the first time on preterm born babies in neonatal intensive care. This achievement reflects years of development and our ability to navigate complex regulatory pathways. In parallel, we completed a successful directed share issue of approximately SEK 20 million, supported by new institutional investors, including Cicero Fonder and Adrigo Fonder, as well as existing shareholders, including Anmiro AB. Their participation complements our strong shareholder base and reflects long-term confidence in Neola Medical and our mission,” says CEO Hanna Sjöström.
Read more in the Investor letter spring 2025, attached to this press release and available on the company’s website www.neolamedical.com